Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Prostatype Genomics AB의 CEO는 누구입니까?
Fredrik Persson은 2017부터 회사에 합류한 Prostatype Genomics AB의 Chief Executive Officer입니다.
PGABF 주식의 가격 성능은 어떻습니까?
PGABF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Prostatype Genomics AB의 주요 사업 주제나 업종은 무엇입니까?
Prostatype Genomics AB은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
